Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 18/20 | 1.00 |
| ▸ | BCL2 | P10415 | 9/20 | 1.00 |
| ▸ | MDM4 | O15151 | 1/20 | 1.00 |
| ▸ | BCL2L11 | O43521 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | BID | P55957 | 1/20 | 1.00 |
| ▸ | BAX | Q07812 | 1/20 | 1.00 |
| ▸ | MCL1 | Q07820 | 1/20 | 1.00 |
| ▸ | ASPH | Q12797 | 1/20 | 1.00 |
| ▸ | BECN1 | Q14457 | 1/20 | 1.00 |
| ▸ | BAK1 | Q16611 | 1/20 | 1.00 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 1.00 |
| ▸ | BAD | Q92934 | 1/20 | 1.00 |
| ▸ | BBC3 | Q9BXH1 | 1/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.88 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.88 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.88 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.88 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.88 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Abt 737 SCHEMBL170470 | 1.00 | BCL2L1 (1.00) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| Abt 737 SCHEMBL29355185 | 1.00 | BCL2L1 (1.00) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| Abt 737 SCHEMBL1541072 | 1.00 | BCL2L1 (1.00) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| SCHEMBL1540670 | 0.97 | BCL2L1 (0.93) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| SCHEMBL1540214 | 0.96 | BCL2L1 (0.92) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| SCHEMBL1540387 | 0.96 | BCL2L1 (0.92) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| SCHEMBL1540510 | 0.96 | BCL2L1 (1.00) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| SCHEMBL1540736 | 0.96 | BCL2L1 (1.00) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| SCHEMBL1541579 | 0.95 | BCL2L1 (0.91) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| SCHEMBL26648550 | 0.95 | BCL2L1 (0.91) | BCL2L1BCL2MDM4BCL2L11TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4582 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146233-A1 | HIF-1a STABILIZATION FOR TISSUE REGENERATION | THE UNIVERSITY OF HONG KONG (CN) | 2026-05-28 | — | — | US | claimed |
| EP-3429570-B1 | COMBINATIONS OF LSD1 INHIBITORS FOR THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES | ORYZON GENOMICS SA (ES) | 2026-05-20 | — | — | EP | claimed |
| CN-122028938-A | Pharmaceutical combination comprising an anti-CD 37 antibody maytansinoid conjugate and a BCL2 inhibitor or PI3K inhibitor | 德彪药业国际股份公司 | 2026-05-12 | — | — | CN | claimed |
| CN-122028920-A | Method for treating hematological cancer | 丹娜-法伯癌症研究院 | 2026-05-12 | — | — | CN | claimed |
| US-20260124242-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES FROM LIQUID TUMORS AND THERAPEUTIC USES THEREOF | IOVANCE BIOTHERAPEUTICS INC (US) | 2026-05-07 | — | — | US | claimed |
| EP-4727563-A1 | AGENTS FOR USE IN A METHOD OF TREATING AN ACUTE LIVER DISEASE SUBJECT | Beatson Institute for Cancer Research (GB) | 2026-04-22 | — | — | EP | claimed |
| US-12605460-B2 | Stem cell-nano drug delivery system complex, use thereof and method for preparing the same | GACHON UNIVERSITY OF INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2026-04-21 | — | — | US | claimed |
| EP-4719403-A1 | METHODS OF TREATING CANCER IN BCL2 INHIBITOR NAIVE SUBJECTS | Curis, Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| US-12595517-B2 | Method to treat and stratify a patient suffering from a cancer | INSERM (INSTITUTE NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2026-04-07 | — | — | US | claimed |
| EP-4714447-A1 | DRUG COMBINATIONS OF BCL-XL INHIBITORS FOR TREATMENT OF CANCER | Stichting Amsterdam UMC (NL) | 2026-03-25 | — | — | EP | claimed |
| US-20100028889-A1 | COMPANION DIAGNOSTIC ASSAYS FOR CANCER THERAPY | ABBOTT LABORATORIES (US) | 2010-02-04 | — | — | US | claimed |
| US-7642260-B2 | N-acylsulfonamide derivatives; BCL-X1 protein inhibitors; anticarcinogenic agents; bladder cancer; for example, N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)-propyl)amino)-3-nitrobenzenesulfonamide | ABBOTT LABORATORIES, INC. (US) | 2010-01-05 | — | — | US | claimed |
| US-20090176785-A1 | METHOD OF TREATING ARTHRITIS | ABBOTT LABORATORIES (US) | 2009-07-09 | — | — | US | claimed |
| US-20080199873-A1 | Companion diagnostic assays for cancer therapy | ABBOTT LABORATORIES | 2008-08-21 | — | — | US | claimed |
| US-20080182845-A1 | METHOD OF PREVENTING OR TREATING ORGAN, HEMATOPOIETIC STEM CELL OR BONE MARROW TRANSPLANT REJECTION | ABBOTT LABORATORIES (US) | 2008-07-31 | — | — | US | claimed |
| US-20070072860-A1 | N-acylsulfonamide derivatives; BCL-X1 protein inhibitors; anticarcinogenic agents; bladder cancer; for example, N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)-propyl)amino)-3-nitrobenzenesulfonamide | ABBOTT LABORATORIES | 2007-03-29 | — | — | US | claimed |
| US-20070015787-A1 | Apoptosis promoters | ABBVIE INC. | 2007-01-18 | — | — | US | claimed |
| US-20060258657-A1 | Apoptosis promoters | ABBVIE INC. | 2006-11-16 | — | — | US | claimed |
| US-20060128706-A1 | Apoptosis promoters | ABBVIE INC. | 2006-06-15 | — | — | US | claimed |
| US-20050159427-A1 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES | 2005-07-21 | — | — | US | claimed |